UNSPSC 51171704: Nifuroxazide

This classification denotes a topical anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PM5LI0P38J. European Medicines Agency schedules Nifuroxazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09271MIG. Nifuroxazide generally arises in the molecular formula C12H9N3O5. The term NIFUROXAZIDE is an International Non-Proprietary Name or INN. NIFUROXAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule nifuroxazide under HS 29321900 and SITC 51569. As of Q4 2014, NIFUROXAZIDE remains the US FDA Preferred Term for this commodity. Nifuroxazide bears US NLM identifiers UMLS ID C0068742 and NCI Concept Code C90982. SMILES: O1C(CCC1[N](=O)O)/C=N/NC(=O)C1CCC(O)CC1.

UNSPSC 51171704 Nifuroxazide is a Commodity code that maps poorly to recent state and local procurement activity. The three most recent opportunities tagged under this code involve offender drug testing services (specimen collection and immunoassay screening), direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals distributed through wholesalers — none of which constitute procurement of nifuroxazide, a narrow-spectrum antibiotic, as a discrete product line. The code shows no relevant recent activity targeting nifuroxazide specifically.

Recent opportunities instead reflect state and local governments' actual spending on pharmaceutical distribution infrastructure, testing services, and benefit-program administration. Collin County Community Supervision and Corrections Department issued an RFP for offender specimen collection and drug testing services (due July 23, 2026, estimated value $600,000 over two years with renewal options), the Texas Health and Human Services Commission posted a Request for Information on direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance issued an RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (proposals due March 26, 2026). These solicitations target system-level procurement — testing capacity, benefit administration, and broad pharmaceutical supply — rather than individual active pharmaceutical ingredients. The code does not appear to reflect current state and local procurement demand.